市場調查報告書
商品編碼
1491669
裸金屬支架市場:按產品、最終用戶分類 - 2024-2030 年全球預測Bare-metal Stents Market by Product (Balloon Catheter, Balloon Expendable Stent, Metallic Stent), End Users (Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Hospitals) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
裸金屬支架市場規模預計2023年為62.3億美元,預計2024年將達到65.7億美元,2030年將達到91.7億美元,複合年成長率為5.66%。
裸金屬支架是小型網狀金屬管,用於醫療手術中以支撐和打開阻塞的動脈。這種類型的支架通常在血管成形術中使用,以治療冠狀動脈疾病引起的動脈狹窄和阻塞。支架恢復血流並防止動脈狹窄。與藥物釋放型支架不同,裸金屬支架沒有將藥物釋放到動脈中的塗層;它們只是由金屬材料製成。全球範圍內冠狀動脈疾病等心血管疾病的增加推動了對裸金屬支架的需求。這些疾病仍然是全球死亡的主要原因之一,因此置入術等有效、微創解決方案的需求至關重要,並且持續成長。然而,由於產品召回,裸金屬支架面臨重大挑戰。此類召回通常是由於設備故障或可能對患者造成傷害的安全問題造成的。此外,裸金屬支架製造技術的改進使得產品更加精確可靠。雷射切割和改進的生物相容性材料等技術使這些支架越來越耐腐蝕,確保更好的患者治療效果。
主要市場統計 | |
---|---|
基準年[2023] | 62.3億美元 |
預計年份 [2024] | 65.7億美元 |
預測年份 [2030] | 91.7億美元 |
複合年成長率(%) | 5.66% |
區域洞察
在美洲,美國和加拿大在裸金屬支架市場中佔有重要地位,反映出其醫療保健系統成熟且心血管疾病盛行率較高。美洲的消費者傾向於微創手術,從而推動了支架需求。最近的投資主要集中在先進技術和降低血管再阻塞的風險。市場滲透率高,品質和品牌聲譽受到重視並影響購買行為。另一方面,EMEA市場豐富多樣性,嚴格的監管在塑造市場方面發揮重要作用。最近的歐盟醫療設備法規影響了置入術的實踐,強調安全性和有效性。消費者信心高度依賴監管部門的核准,穩定的需求符合醫療保健法規。此外,亞太地區人口眾多且老化增加了心血管疾病的盛行率,導致對使用裸金屬支架治療的需求增加。在中國和印度等人口眾多的國家,由於城市生活方式的轉變以及高血壓、糖尿病和肥胖等危險因子的增加,冠狀動脈病例數量不斷增加。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在裸金屬支架市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對裸金屬支架市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在裸金屬支架市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[184 Pages Report] The Bare-metal Stents Market size was estimated at USD 6.23 billion in 2023 and expected to reach USD 6.57 billion in 2024, at a CAGR 5.66% to reach USD 9.17 billion by 2030.
A bare-metal stent is a small, mesh-like metal tube used in medical procedures to support and keep open a blocked artery. This type of stent is often used during a procedure called angioplasty to treat arteries that have been narrowed and blocked due to coronary artery disease. The stent helps restore blood flow and prevents the artery from narrowing. Unlike drug-eluting stents, bare-metal stents do not have a coating that releases medication into the artery; they are simply made of metal materials. The rising prevalence of cardiovascular conditions, such as coronary artery diseases, across the globe acts as a primary driver for the demand for bare-metal stents. As these diseases remain among the leading causes of death worldwide, the need for effective, minimally invasive solutions such as stenting is crucial and continues to grow. However, bare-metal stents have faced significant challenges due to product recalls. Such recalls often stem from issues related to device malfunctions or safety concerns that could potentially harm patients. Moreover, the improvements in manufacturing technologies for bare-metal stents have allowed for more precise and reliable products. With techniques such as laser cutting and improved biocompatible materials, these stents are increasingly effective in resisting corrosion and ensuring better patient outcomes.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 6.23 billion |
Estimated Year [2024] | USD 6.57 billion |
Forecast Year [2030] | USD 9.17 billion |
CAGR (%) | 5.66% |
Regional Insights
In the Americas, the United States and Canada are significant players in the bare-metal stents market, reflecting a mature healthcare system and high incidence rates of cardiovascular diseases. Consumers in the Americas are inclined towards minimally invasive procedures, driving demand for stents. Recent investments have focused on technological advancements and reducing the risk of restenosis. Market penetration is high, and the focus is on quality and brand reputation, influencing purchasing behaviors. On the other hand, the EMEA market is diverse, with regulatory rigor playing a critical role in shaping the market. Recent EU Medical Device Regulations have impacted stenting practices, with a strong emphasis on safety and efficacy. Consumer trust is highly dependent on regulatory approvals, and a steady demand is aligned with healthcare provisions. Moreover, the Asia Pacific region has a large and aging population, which increases the prevalence of cardiovascular diseases and, thus, the demand for interventions involving bare-metal stents. Countries such as China and India, with their vast populations, are seeing higher numbers of coronary artery cases due to shifts towards urban lifestyles and increased occurrences of risk factors such as hypertension, diabetes, and obesity.
Market Insights
The market dynamics represent an ever-changing landscape of the Bare-metal Stents Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bare-metal Stents Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bare-metal Stents Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Boston Scientific's AGENT Drug-Coated Balloon, Enhancing Peripheral Artery Disease Treatments
Boston Scientific has received FDA approval for its AGENT Drug-Coated Balloon, a pivotal development in treating peripheral artery disease (PAD). This new medical device is designed to maintain arterial openness and prevent re-blockage, addressing a common issue in PAD therapies. The approval is based on positive outcomes from clinical trials that demonstrated significant improvements in patient conditions with minimal risks. This development marks a significant milestone in vascular medicine, promising enhanced treatment solutions for patients suffering from arterial diseases. [Published On: 2024-03-01]
Kaneka Corporation Enhances Stent Development Capabilities with Acquisition of JMDT
Kaneka Corporation enhanced its position in the medical device sector by acquiring all shares of Japan Medical Device Technology Co., Ltd. (JMDT), a prominent developer and manufacturer of medical devices located in Kamimashiki-gun, Kumamoto. This strategic acquisition positions Kaneka as a fully integrated company in the endovascular catheter market, particularly focusing on coronary artery disease treatments through stenting, a segment worth 30 billion yen in Japan. [Published On: 2023-11-30]
FDA Greenlights Medinol's Innovative Drug-Eluting Coronary Stent
The U.S. Food and Drug Administration (FDA) has officially approved the use of Medinol's latest drug-eluting stent in coronary artery interventions. This state-of-the-art stent integrates medication that actively prevents artery re-blockage, a common issue post-surgery. Key features of the stent include its enhanced design, which significantly betters its flexibility and positioning accuracy compared to traditional bare-metal stents. This approval marks a significant milestone in coronary treatment options, offering enhanced effectiveness and safety, thereby improving patient outcomes in managing coronary artery disease. [Published On: 2023-10-24]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bare-metal Stents Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Bare-metal Stents Market, highlighting leading vendors and their innovative profiles. These include Abott Laboratories, ACE CARDIOPATHY, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Medtronic PLC, MeKo Manufacturing e.K., Meril Life Sciences Pvt Ltd., MicroPort Scientific Corporation, Relisys Medical Devices Limited, SLTL Group, STENTYS SA, Stryker Corporation, Terumo Corporation, and Translumina Therapeutics.
Market Segmentation & Coverage